Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Trial Profile

A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2019

At a glance

  • Drugs BAN 2401 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biogen; Eisai Co Ltd; Eisai Inc
  • Most Recent Events

    • 11 Jul 2019 Planned primary completion date changed from 1 Aug 2021 to 1 Aug 2020.
    • 18 Jun 2019 Planned End Date changed from 1 Aug 2021 to 24 Nov 2021.
    • 22 Mar 2019 According to an Eisai Inc media release, the study design for the Open Label Extension portion will be highlighted at the 14th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD) on 26-31 March, 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top